GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)
GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)
Recruiting · NCT07058298 · Registry updated 2025-09-08Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103) | Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Recruiting | Early phase 1 | 2025-09-08 | NCT07058298 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Daishi Tian | 6 |
| Gracell Biotechnologies (Shanghai) Co., Ltd. | 11 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Tongji Hospital of Tongji Medical Colledge, Huazhong University of Science and Technology | Wuhan | China | 1 |